Endocrine Abstracts

Background and Aims: Non-alcoholic fatty liver disease (NAFLD), a leading cause of cirrhosis and liver cancer, is increasing worldwide due to rising obesity rates, particularly in Asia. Weight loss induced with diet and exercise decreases hepatic steatosis and inflammation, but requires greater efforts to sustain compared to medication. We therefore aimed to compare the effects of liraglutide, a glucagon-like peptide-1 agonist which induces weight loss, on hepatic steatosis an...